We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+11.2%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$9.54B
AUM Growth
+$718M
Cap. Flow
-$27.8M
Cap. Flow %
-0.29%
Top 10 Hldgs %
34.85%
Holding
152
New
15
Increased
35
Reduced
32
Closed
15

Top Buys

Rank Stock Value
1
CI icon
Cigna
CI
+$196M
2
CLVS
Clovis Oncology, Inc.
CLVS
+$129M
3
GILD icon
Gilead Sciences
GILD
+$84.7M
4
VTRS icon
Viatris
VTRS
+$64.4M
5
BIIB icon
Biogen
BIIB
+$51.1M

Top Sells

Rank Stock Value
1
CNC icon
Centene
CNC
+$118M
2
PFE icon
Pfizer
PFE
+$98M
3
HCA icon
HCA Healthcare
HCA
+$97.1M
4
THC icon
Tenet Healthcare
THC
+$94.8M
5
AGN.PRA
Allergan plc
AGN.PRA
+$73.9M

Sector Composition

Rank Sector Weight
1 Healthcare 92.6%
2 Financials 1.77%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DMTX
101
DELISTED
Dimension Therapeutics, Inc
DMTX
$7.83M 0.08%
5,397,698
– –
VRNA
102
DELISTED
Verona Pharma
VRNA
$7.77M 0.08%
+666,666
New +$8.83M
LAB icon
103
Standard BioTools
LAB
$342M
$7.05M 0.07%
1,746,100
– –
ZBH icon
104
Zimmer Biomet
ZBH
$18.8B
$6.29M 0.07%
50,470
– –
SNDX icon
105
Syndax Pharmaceuticals
SNDX
$1.7B
$6.11M 0.06%
437,000
-47,800
-10% -$546K
CRSP icon
106
CRISPR Therapeutics
CRSP
$4.69B
$5.96M 0.06%
372,191
– –
SYRE icon
107
Spyre Therapeutics
SYRE
$8.5B
$5.66M 0.06%
58,781
– –
NVRO
108
CALL
DELISTED
NEVRO CORP.
NVRO
$5.58M 0.06%
+75,000
New +$6.01M
INFI
109
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$5.1M 0.05%
3,250,300
– –
NUVA
110
DELISTED
NuVasive, Inc.
NUVA
$5.05M 0.05%
65,600
-57,900
-47% -$4.33M
RDHL
111
Redhill Biopharma
RDHL
$4.15M
$4.87M 0.05%
565
– –
SIEN
112
DELISTED
Sientra, Inc.
SIEN
$4.7M 0.05%
48,335
-3,891
-7% -$318K
HALO icon
113
Halozyme
HALO
$9.88B
$4.49M 0.05%
+350,000
New +$4.67M
NVTA
114
DELISTED
Invitae Corporation
NVTA
$4.37M 0.05%
456,666
– –
SRRA
115
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$4.33M 0.05%
92,593
– –
TSRO
116
DELISTED
TESARO, Inc.
TSRO
$4.24M 0.04%
30,301
-16,899
-36% -$2.45M
CBIO
117
Crescent Biopharma
CBIO
$546M
$3.77M 0.04%
+3,376
New +$2.79M
AFMD
118
DELISTED
Affimed
AFMD
$3.69M 0.04%
179,970
-21,920
-11% -$487K
BHC icon
119
Bausch Health
BHC
$1.75B
$3.37M 0.04%
194,900
– –
NERV icon
120
Minerva Neurosciences
NERV
$191M
$3.05M 0.03%
43,022
-45,016
-51% -$2.91M
ROKA
121
DELISTED
Sorrento Tech, Inc. Common Stock
ROKA
$2.31M 0.02%
893,470
– –
XENE icon
122
Xenon Pharmaceuticals
XENE
$6.1B
$2M 0.02%
634,812
– –
CLLS
123
Cellectis
CLLS
$288M
$1.73M 0.02%
66,799
-283,201
-81% -$6.76M
NVLN
124
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
$923K 0.01%
100,000
– –
BLRX
125
BioLineRX
BLRX
$12M
$878K 0.01%
1,731
– –
2 3 4
5
6

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q2 2017 Portfolio in Review

As of Q2 2017, OrbiMed held 152 positions worth $9.54B, up 8.1% from $8.82B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

OrbiMed's Q2 2017 filing shows 15 new, 35 increased, 32 reduced and 15 closed positions. Its largest new stake was Cigna: 1,222,100 shares worth $205M. The largest sale was Centene, an estimated $118M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 93% a quarter earlier, followed by Financials.

  • OrbiMed's largest Q2 2017 buy was Cigna: 1,222,100 shares worth $205M.
  • OrbiMed added most to Gilead Sciences in Q2 2017, an estimated $84.7M increase.
  • OrbiMed's biggest Q2 2017 reduction was Pfizer, cutting an estimated $98M.
  • OrbiMed fully exited Centene in Q2 2017, selling an estimated $118M.
  • OrbiMed's ten largest holdings make up 35% of its $9.54B portfolio in Q2 2017.
  • OrbiMed opened 15 new positions and closed 15 in Q2 2017.
  • OrbiMed's portfolio value rose 8.1% quarter-over-quarter to $9.54B.

Based on OrbiMed's 13F filing for Q2 2017, filed 14 Aug 2017.